share_log

Advaxis (NASDAQ:ADXS) Coverage Initiated at StockNews.com

kopsource ·  Sep 20, 2022 01:31

StockNews.com assumed coverage on shares of Advaxis (NASDAQ:ADXS – Get Rating) in a report published on Friday. The firm issued a sell rating on the stock.

Advaxis Price Performance

Shares of ADXS stock opened at $2.86 on Friday. The company has a market cap of $5.19 million, a P/E ratio of -0.32 and a beta of 2.20. Advaxis has a twelve month low of $1.02 and a twelve month high of $44.80.

Get Advaxis alerts:

Advaxis Company Profile

(Get Rating)

Advaxis, Inc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer.

See Also

  • Get a free copy of the StockNews.com research report on Advaxis (ADXS)
  • Lucid is Looking Like a Clear EV Winner
  • Still Lovin' It: Investors Keep Visiting McDonald's
  • Did FedEx Just Deliver A Buying Opportunity?
  • Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
  • Upwork Shares Stumble into Bargain Territory

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment